Erin Weeda to Rivaroxaban
This is a "connection" page, showing publications Erin Weeda has written about Rivaroxaban.
Connection Strength
3.150
-
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis. J Thromb Thrombolysis. 2020 Apr; 49(3):360-364.
Score: 0.666
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.532
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.521
-
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Int J Cardiol. 2016 Nov 01; 222:846-849.
Score: 0.517
-
Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Curr Med Res Opin. 2016 06; 32(6):1117-20.
Score: 0.503
-
Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.
Score: 0.150
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.131
-
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism? Clin Appl Thromb Hemost. 2017 Oct; 23(7):830-837.
Score: 0.129